CyBeR Association in Relapsed/Refractory DLBCL

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

PHASE2

Total Enrollment

78 participants

Study Classification

INTERVENTIONAL

Study Start Date

2016-06-30

Study Completion Date

2018-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Forty percent of patients with diffuse large B cell lymphoma (DLBCL) have primary refractory or relapsed disease (R/R). For these fit patients, standard treatment in second line therapy is high dose therapy with autologous stem cell transplantation (ASCT). In 48% of DLBCL no ASCT is possible due to progressive disease. For these patients or ineligible to transplantation patients, salvage therapy is often rituximab-gemcitabine-oxaliplatine regimen with an overall response rate (ORR) about 50%.

Bendamustine in combination with rituximab, used as a single agent in the setting of R/R DLBCL patients, have shown an ORR of 62.7% and 45.8% with a good safety profile.

Bendamustine and cytarabine (BAC) showed high synergy in inducing cell death in mantle cell lymphoma and DLBCL cell lines. In a recent phase II study, the combination of cytarabine with Rituximab and Bendamustine (R-BAC) in patients with mantle cell lymphoma who were previously untreated, refractory or relapsed was evaluated.

The efficacy and safety of the R-BAC association will be evaluated in this phase II trial enrolling 78 patients with relapsed or refractory DLBCL.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Bendamustine + Rituximab in Older Patients With Previously Untreated Diffuse Large B-cell Lymphoma

NCT01234467

Diffuse Large B-Cell Lymphoma Lymphoma, Diffuse Large-Cell Diffuse Large-Cell Lymphoma +1 more

COMPLETED PHASE2

Study of SyB L-0501 in Combination With Rituximab to Treat Relapsed/Refractory Diffuse Large B-Cell Lymphoma

NCT01118845

Non-Hodgkin's Lymphoma Lymphoma, Large Cell Diffuse, Mantle Cell Lymphoma, Lymphoma +2 more

COMPLETED PHASE2

Ibrutinib in Combination With Lenalidomide and Rituximab in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma

NCT02077166

Relapsed Diffuse Large B-Cell Lymphoma Refractory Diffuse Large B-Cell Lymphoma

COMPLETED PHASE1/PHASE2

Ibrutinib and Lenalidomide With Dose Adjusted EPOCH-R in Subjects With Relapsed/Refractory Diffuse Large B-cell Lymphoma

NCT02142049

Diffuse Large B Cell Lymphoma Relapsed Diffuse Large B Cell Lymphoma Refractory

COMPLETED PHASE1/PHASE2

Bendamustine Combined With Rituximab for Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma

NCT00831597

Diffuse Large B-Cell Lymphoma

COMPLETED PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Participants will received 6 cycles every 21 days with a follow-up period of 24 months.

CT-Scan after 3 cycles and at the end of the treatment will be used to assess treatment response, established with Cheson criteria in 1999.

Principal objective is to obtain an overall response rate of 60% (corresponding to an increased of 15% of the rituximab-gemcitabine-oxaliplatine regimen's overall response rate).

Secondaries objectives are to value toxicity, progression free survival and overall survival.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Diffuse Large B Cell Lymphoma

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

DLBCL patients

they will receive a combination of: Rituximab 375mg/m2 IV at Day 1 Bendamustine 90mg/m2 IV at Day 1 and 2 Cytarabine 1000mg/m2 IV at day 2 every 21 days for 6 cycles

Group Type EXPERIMENTAL

Rituximab

Intervention Type DRUG

375mg/m2 IV day 1

Bendamustine

Intervention Type DRUG

90mg/m2 IV day 1-2

Cytarabine

Intervention Type DRUG

1000mg/m2 or 750mg/m2 at day 2 if patients aged more than 70 years or toxicity grade 3/4

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Rituximab

375mg/m2 IV day 1

Intervention Type DRUG

Bendamustine

90mg/m2 IV day 1-2

Intervention Type DRUG

Cytarabine

1000mg/m2 or 750mg/m2 at day 2 if patients aged more than 70 years or toxicity grade 3/4

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

mabthera levact aracytine

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. patients from 18 to 75 years
2. Patient sharpened the social security system
3. Patients with relapsed or refractory diffuse large B cell lymphoma who received at least one prior line of immunochemotherapy unfit for intensive regimen therapy and autologous stem cell transplantation (ASCT) eligible patients to stem cell transplantation with failure of the salvage therapy patients with relapse after ASCT
4. Not previously treated with bendamustine
5. WHO performance status 0, 1 or 2
6. Adequate hematological function as defined by: leucocyte count ≥ 3.0 109/L, platelet count ≥ 75 109/L
7. Females of childbearing potential must agree to have a medically acceptable method of contraception from study treatment initiation until the end of treatment.
8. Signed informed consent.

Exclusion Criteria

1. Person under guardianship or curatorship , or unable to understand the purpose of the study
2. Central nervous system or meningeal involvement
3. WHO performance status more than 2
4. Contraindication to any drug contained in the chemotherapy regimen
5. HIV disease, active hepatitis B or C
6. Any serious active disease or co-morbid medical condition
7. Any of the following laboratory abnormalities.

* Leucocyte count \< 3.0 x 109/L
* Platelet count \< 75 x 109/L
8. Any serious medical condition, laboratory abnormality, or psychiatric illness that would prevent the subject from signing the informed consent form.
9. Pregnant or lactating females.
10. Prior history of malignancies, other than lymphoma, unless the patient has been free of the disease for ≥ 3 years. Exceptions include the following:

* Basal cell carcinoma of the skin.
* Squamous cell carcinoma of the skin.
* Carcinoma in situ of the cervix.
* Carcinoma in situ of the breast.
* Incidental histological finding of prostate cancer (TNM stage of T1a or T1b).
11. renal impairment with an estimated (modified dietin renal disease; MDRD) creatinine clearance \< 40 ml/min,
12. chronic liver disease or day-1 (AST/ALT )≥2.5 upper limit of normal (ULN), total bilirubin≥1.5 ULN,

Minimum Eligible Age

18 Years

Maximum Eligible Age

75 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No